Literature DB >> 16156882

The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy.

M J Parsonage1, E G L Wilkins, N Snowden, B G Issa, M W Savage.   

Abstract

We report two cases in which osteomalacia developed in patients on tenofovir-containing highly active antiretroviral therapy (HAART) in the context of Fanconi syndrome with hypophosphataemia. Bone pain was the presenting feature and myopathy followed in one case. Disability was reversed with withdrawal of the drug and with mineral supplementation. The cases highlight the importance of considering the diagnosis of osteomalacia in patients treated with tenofovir. A possible association with incipient acute renal failure, particularly during nonsteroidal anti-inflammatory drug (NSAID) use, needs further investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16156882     DOI: 10.1111/j.1468-1293.2005.00318.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  32 in total

1.  Fanconi's Syndrome Associated with Prolonged Adefovir Dipivoxil Therapy in a Hepatitis B Virus Patient.

Authors:  Young Kul Jung; Jong Eun Yeon; Jong Hwan Choi; Chung Ho Kim; Eun Suk Jung; Ji Hoon Kim; Jong Jae Park; Jae Seon Kim; Young-Tae Bak; Kwan Soo Byun
Journal:  Gut Liver       Date:  2010-09-24       Impact factor: 4.519

2.  Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.

Authors:  Andrés Duarte-Rojo; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

3.  In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.

Authors:  Francesc Vidal; Joan Carles Domingo; Jordi Guallar; Maria Saumoy; Begoña Cordobilla; Rainel Sánchez de la Rosa; Marta Giralt; Maria Luisa Alvarez; Miguel López-Dupla; Ferran Torres; Francesc Villarroya; Tomas Cihlar; Pere Domingo
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

4.  Clinical and laboratory features of patients with osteomalacia initially presenting with neurological manifestations.

Authors:  S W Kim; N Hong; Y Rhee; Y-C Choi; H Y Shin; S M Kim
Journal:  Osteoporos Int       Date:  2018-04-05       Impact factor: 4.507

Review 5.  Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.

Authors:  Atefeh Jafari; Hossein Khalili; Simin Dashti-Khavidaki
Journal:  Eur J Clin Pharmacol       Date:  2014-06-25       Impact factor: 2.953

Review 6.  Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?

Authors:  Jérôme Tourret; Gilbert Deray; Corinne Isnard-Bagnis
Journal:  J Am Soc Nephrol       Date:  2013-09-19       Impact factor: 10.121

7.  Development of osteomalacia in a post-liver transplant patient receiving adefovir dipivoxil.

Authors:  Masami Minemura; Yoshiharu Tokimitsu; Kazuto Tajiri; Yasuhiro Nakayama; Kengo Kawai; Hiroshi Kudo; Katsuharu Hirano; Yoshinari Atarashi; Yutaka Yata; Satoshi Yasumura; Terumi Takahara; Toshiro Sugiyama
Journal:  World J Hepatol       Date:  2010-12-27

8.  Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients.

Authors:  Lourdes Mateo; Susana Holgado; Maria Luisa Mariñoso; Ricard Pérez-Andrés; Anna Bonjoch; Joan Romeu; Alejandro Olivé
Journal:  Clin Rheumatol       Date:  2014-05-03       Impact factor: 2.980

9.  Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report.

Authors:  Antonio Di Biagio; Raffaella Rosso; Patrizia Monteforte; Rodolfo Russo; Guido Rovetta; Claudio Viscoli
Journal:  J Med Case Rep       Date:  2009-07-22

10.  Tenofovir-associated bone density loss.

Authors:  Iwen F Grigsby; Lan Pham; Louis M Mansky; Raj Gopalakrishnan; Kim C Mansky
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.